KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Amortization of Deferred Charges: 2013-2025

Historic Amortization of Deferred Charges for Ionis Pharmaceuticals (IONS) over the last 13 years, with Sep 2025 value amounting to $1.7 million.

  • Ionis Pharmaceuticals' Amortization of Deferred Charges fell 1.55% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 0.99%. This contributed to the annual value of $6.7 million for FY2024, which is 5.69% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $1.7 million for Q3 2025, which was up 0.36% from $1.6 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $1.7 million for Q3 2023, and its period low was $860,000 during Q1 2021.
  • Over the past 3 years, Ionis Pharmaceuticals' median Amortization of Deferred Charges value was $1.7 million (recorded in 2023), while the average stood at $1.6 million.
  • In the last 5 years, Ionis Pharmaceuticals' Amortization of Deferred Charges surged by 61.79% in 2021 and then declined by 3.30% in 2022.
  • Ionis Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $1.4 million in 2021, then dropped by 2.48% to $1.3 million in 2022, then rose by 24.36% to $1.7 million in 2023, then grew by 0.60% to $1.7 million in 2024, then fell by 1.55% to $1.7 million in 2025.
  • Its Amortization of Deferred Charges stands at $1.7 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.6 million for Q1 2025.